The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease

Wei-Feng Liang, Li-Juan Wang, Hui Li, Chang-Hao Liu, Miao-Fang Wu, Jing Li, Wei-Feng Liang, Li-Juan Wang, Hui Li, Chang-Hao Liu, Miao-Fang Wu, Jing Li

Abstract

Objective: To investigate whether CA125 normalization following neoadjuvant chemotherapy (NACT) can complement the chemotherapy response system (CRS) in the prognostication of patients with tubo-ovarian high-grade serous carcinoma (HGSC). Methods: In total, 118 HGSC patients who received NACT followed by interval debulking surgery (IDS) for FIGO stage IIIC-IV disease were included, and their clinical data were retrospectively reviewed. The primary endpoint was progression-free survival (PFS). Cox regression analysis was performed to identify predictors of PFS. Results: Following NACT, CRS3 was noted in 35 patients (29.7%), and CA125 normalization (≤ 35 U/ml) was noted in 54 patients (45.8%). Both CRS3 and CA125 normalization were identified as independent prognosticators of PFS. Combining these two factors, we stratified the 106 patients into three groups with different risks of recurrence: low-risk group (CRS3 + post-NACT CA125≤ 35 U/ml; n = 17, 14.4%), intermediate-risk group (CRS3 + post-NACT CA125 > 35 U/ml; n = 19, 16.1%) and high-risk group (CRS1-2; n= 82, 69.5%). The differences in PFS between the three groups were significant (log-rank test, P < 0.0001). In Cox regression analyses, the new stratification method was found to have an independent prognostic effect. Conclusion: Both the CRS system and the normalization of CA125 following NACT could reliably predict the risk of recurrence following primary treatment. The combination of the two factors refined the prognostic stratification of HGSC patients who were treated with NACT and IDS.

Keywords: biomarkers; chemotherapy; gynecologic oncology; prognosis.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

© The author(s).

Figures

Figure 1
Figure 1
Kaplan‐Meier curves for progression‐free survival (PFS) and overall survival (OS). (A) PFS according to chemotherapy response score (CRS). (B) PFS according to post-NACT CA125 level. (C) OS according to chemotherapy response score (CRS). (D) OS according to post-NACT CA125 level. NACT, neoadjuvant chemotherapy.
Figure 2
Figure 2
Kaplan‐Meier curves for progression‐free survival (PFS). (A) The patients were divided into four subgroups based on their chemotherapy response score (CRS) and post-NACT CA125 level. (B) The patients were stratified into low-, intermediate-, and high-risk categories. NACT, neoadjuvant chemotherapy.

References

    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F. et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
    1. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Journal of the National Comprehensive Cancer Network. 2020. 18.
    1. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv259.
    1. Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J. et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010;119:38–42.
    1. Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer. 2010;46:102–9.
    1. Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119:259–64.
    1. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249–57.
    1. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.
    1. Fagotti A, Vizzielli G, Ferrandina G, Fanfani F, Gallotta V, Chiantera V, Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial) J Clin Oncol. 2018. 36, no. 15_suppl 5516.
    1. Dizon DS. Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection. Gynecol Oncol. 2017;144:241–2.
    1. Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage W, McNeish I. et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology. 2019;30:672–705.
    1. Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A. et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. Journal of Clinical Oncology. 2015;33:2457–63.
    1. Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ. et al. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol. 2017;28:e73.
    1. Santoro A, Angelico G, Piermattei A, Inzani F, Valente M, Arciuolo D. et al. Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease. Front Oncol. 2019;9:778.
    1. Cohen PA, Powell A, Bohm S, Gilks CB, Stewart CJR, Meniawy TM. et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019;154:441–8.
    1. Zorzato PC, Zannoni GF, Tudisco R, Pasciuto T, Di Giorgio A, Franchi M. et al. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response. Int J Gynecol Cancer. 2020;30:67–73.
    1. Rajkumar S, Polson A, Nath R, Lane G, Sayasneh A, Jakes A. et al. Prognostic implications of histological tumor regression (Bohm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma. Gynecol Oncol. 2018;151:264–8.
    1. Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, Zorn KK, Kelley JL, Richard SD. et al. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. Int J Gynecol Cancer. 2011;21:1013–7.
    1. Van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn H, Dobler-Girdziunaite D. et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecologic oncology. 2000;79:444–50.
    1. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL. et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3460–73.
    1. INTEGRITY S. Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Histopathology Reporting Guide.
    1. Dewdney SB, Rimel BJ, Reinhart AJ, Kizer NT, Brooks RA, Massad LS. et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol. 2010;119:18–21.
    1. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC. et al. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016;34:3854–63.
    1. Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13:255–61.
    1. Zhang GN, Liu H, Huang JM, Wang L, Zhao JS, Li C. et al. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Gynecol Oncol. 2014;132:752–7.
    1. Sokolenko AP, Savonevich EL, Ivantsov AO, Raskin GA, Kuligina ES, Gorodnova TV. et al. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. Cancer Lett. 2017;397:127–32.
    1. Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO. et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013;129:63–8.
    1. Luo Y, Lee M, Kim HS, Chung HH, Song YS. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine (Baltimore) 2016;95:e4797.
    1. Onda T, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T. et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020;130:114–25.
    1. Grimm C, Cropet C, Ray-Coquard I. Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial. SGO 2020 Annual Meeting on Women's Cancer. 2020.
    1. Pelissier A, Bonneau C, Chereau E, de La Motte Rouge T, Fourchotte V, Darai E. et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2014;135:542–6.
    1. Zeng J, Yin J, Song X, Jin Y, Li Y, Pan L. Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma. J Cancer. 2016;7:2327–32.
    1. Pelissier A, Roulot A, Guery B, Bonneau C, Bellet D, Rouzier R. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer. J Ovarian Res. 2016;9:61.
    1. Le T, Faught W, Hopkins L, Fung-Kee-Fung M. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer. J Obstet Gynaecol Can. 2008;30:665–70.
    1. Furukawa N, Sasaki Y, Shigemitsu A, Akasaka J, Kanayama S, Kawaguchi R. et al. CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer. J Gynecol Oncol. 2013;24:141–5.
    1. Vallius T, Hynninen J, Auranen A, Carpen O, Matomaki J, Oksa S. et al. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumour Biol. 2014;35:12389–95.
    1. Xu X, Deng F, Lv M, Chen X. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. Arch Gynecol Obstet. 2017;295:451–8.
    1. Stenman UH, Alfthan H, Vartiainen J, Lehtovirta P. Markers supplementing CA 125 in ovarian cancer. Ann Med. 1995;27:115–20.
    1. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103:1070–6.
    1. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H. et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj